07.2025
Why GATC Health
It’s a de-risky business
Drug development is an unequivocably rewarding and inherently risky effort, and it’s at this intersection you’ll find the people that empower it – the investors. But how to make your money work smarter? You supercharge diligence with GATC Health’s Derisq™ AI report. Using the same platform trusted by the world’s largest insurance marketplace to underwrite clinical trial outcomes, Derisq provides detailed predictions into safety, efficacy and off-target risks with about 90% accuracy. That’s flipping the risk/reward script.
Drug development is an unequivocably rewarding and inherently risky effort, and it’s at this intersection you’ll find the people that empower it – the investors. But how to make your money work smarter? You supercharge diligence with GATC Health’s Derisq™ AI report. Using the same platform trusted by the world’s largest insurance marketplace to underwrite clinical trial outcomes, Derisq provides detailed predictions into safety, efficacy and off-target risks with about 90% accuracy. That’s flipping the risk/reward script.
Transforming the future of biotech investment
The Operon™ platform optimizes drug discovery and development by replicating complex systems biology using neural networks and machine learning to predict human outcomes with great precision. The result? Safer and more effective novel therapeutics for sale or licensing for virtually any condition, disease, or disorder.
Capital efficiency
When failure rates are as high as the stakes, biotech's could avoid >80% of wasted R&D spending.
Safer drug candidates, at speed
Leveraging our polypharmacy approach, GATC Health partners can shrink cycle times from discovery to launch from 10-15 years to 3-5 years.
Shrinking costs
The effective cost per approved drug could drop below $300-$500 million using Operon.
Ahead of the game
GATC Health’s AI forecasts clinical trial endpoints before entering the trial stage to support the underwriting risk of future trials.
From data to drug candidates in months, not years
Discover next-generation, multi-target drug candidates for transformative patient outcomes – faster than ever before.
GATC Health AI
Initial Synthesis
In-Vitro
In-Vivo
FDA IND
Derisq—the investor confidence tool
Discover AI-driven solutions to amplify opportunities and increase returns. Confidence replaces uncertainty with the predictive power of Derisq, with demonstrated 91% sensitivity and 86% specificity scores.
Investing in tomorrow’s innovation
GATC Health deeply understands the unique position of investors and the financial risks that are intrinsically part of medical innovation. By addressing and overcoming these with the power of AI, more treatments can be brought to market. Get in touch to ask for a demo and take the first step towards a more robust return on your investment.
